Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

NCT02477696 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02477696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02477696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Lead sponsor
Acerta Pharma BV
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 28, 2015
Completion date
January 3, 2028
Enrollment
533 (actual)
Sites
130

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia